NetworkNewsBreaks – Champignon Brands Inc. (CSE:
Post# of 25
(Total Views: 253)
Posted On: 10/05/2020 3:15:48 PM
NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Elects Leading International Expert as Board Chairman
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which includes a focus on “breakthrough treatments of depression” through the development of government-approved ketamine compounds and a network of treatment clinics. The company’s dual mission is to develop the next generation of novel psychedelic treatments and delivery systems and help those suffering from mental health disorders in its own ketamine-based clinics.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which includes a focus on “breakthrough treatments of depression” through the development of government-approved ketamine compounds and a network of treatment clinics. The company’s dual mission is to develop the next generation of novel psychedelic treatments and delivery systems and help those suffering from mental health disorders in its own ketamine-based clinics.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Braxia Scientific Corp. (BRAXF) Stock Research Links
Scroll down for more posts ▼